Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001243658 | SCV001416830 | likely benign | Qualitative or quantitative defects of dysferlin | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003145476 | SCV003831246 | uncertain significance | not provided | 2021-04-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004978193 | SCV005571583 | uncertain significance | Inborn genetic diseases | 2024-10-24 | criteria provided, single submitter | clinical testing | The c.496A>C (p.T166P) alteration is located in exon 6 (coding exon 6) of the DYSF gene. This alteration results from a A to C substitution at nucleotide position 496, causing the threonine (T) at amino acid position 166 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001835179 | SCV002079756 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-01-24 | no assertion criteria provided | clinical testing |